Glenmark In-Licenses Cancer Drug Aumolertinib from Hansoh Pharma for Multiple Regions

Strategic Transactions View source PDF Explain this filing

GLENMARK · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.1%Reaction day

₹1962.00

prior close

₹1976.70

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-0.5%-0.5% vs market

Pharmaceuticals peers, median of 156sector-0.8%-0.3% vs sector

On the reaction day the stock moved 0.5 pts less than Nifty Midcap 150 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.9

10m

-0.9

15m

-1.1

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.1-0.5-0.5-0.8-0.3

Next day

-0.2-0.3+0.2-1.0+0.8

+1.5+0.8+0.7-0.1+1.6

+3.8+1.7+2.1+0.2+3.6

+4.3+1.8+2.5+0.5+3.8

+2.7+1.3+1.4+0.0+2.7

+2.4+0.6+1.8-0.9+3.3

15d

+5.7+1.0+4.7-0.4+6.1

+1.2-0.4+1.6-3.7+4.9

+3.7+0.3+3.3-3.7+7.4

+9.3-7.3+16.6-11.3+20.6

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Glenmark's unit GSSA signed an exclusive licensing deal with China's Hansoh Pharma for Aumolertinib, a third-generation lung cancer drug approved in UK and China. Glenmark gets exclusive rights across Middle East, Africa, Southeast and South Asia, Australia, New Zealand, Russia and CIS regions, and some Caribbean nations. Deal terms: low double-digit million USD upfront, milestone payments potentially exceeding USD 1 billion, plus tiered royalties on sales. Boosts Glenmark's oncology portfolio.

Likely market impact

Boosts Glenmark's oncology pipeline across emerging markets, with long-term revenue potential from milestones and royalties, though payout depends on future achievements.